Bio-Rad Laboratories, Inc.
BIO
$265.26
$0.940.36%
NYSE
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 11.31% | -12.30% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.31% | -12.30% | |||
| Cost of Revenue | 11.43% | -15.59% | |||
| Gross Profit | 11.20% | -9.16% | |||
| SG&A Expenses | 6.05% | -5.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.27% | -13.30% | |||
| Operating Income | 39.54% | -1.78% | |||
| Income Before Tax | 396.40% | 109.18% | |||
| Income Tax Expenses | 395.88% | 110.05% | |||
| Earnings from Continuing Operations | 396.56% | 108.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 396.56% | 108.94% | |||
| EBIT | 39.54% | -1.78% | |||
| EBITDA | 26.32% | -2.19% | |||
| EPS Basic | 409.61% | 108.96% | |||
| Normalized Basic EPS | -1.27% | 34.95% | |||
| EPS Diluted | 409.61% | 108.96% | |||
| Normalized Diluted EPS | -1.23% | 34.88% | |||
| Average Basic Shares Outstanding | -2.56% | -0.20% | |||
| Average Diluted Shares Outstanding | -2.60% | -0.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||